Abstract
Bridging the gap between preclinical research and clinical trials is vital for drug development. Predicting clinically relevant steady-state drug concentrations (Css) in serum from preclinical animal models may facilitate this transition. Here we used a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to evaluate the predictive validity of 5-hydroxytryptamine (5-HT; serotonin) transporter (SERT) occupancy and 5-hydroxytryptophan (5-HTP)-potentiated behavioral syndrome induced by 5-HT reuptake inhibitor (SRI) antidepressants in mice.
Originalsprog | Engelsk |
---|---|
Tidsskrift | British Journal of Pharmacology |
Vol/bind | 155 |
Udgave nummer | 2 |
Sider (fra-til) | 276-84 |
Antal sider | 9 |
ISSN | 0007-1188 |
DOI | |
Status | Udgivet - sep. 2008 |